2024
Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease
Swaminathan A, McFatrich M, Mkumba L, Wright L, Redlich C, Snyder L, Reeve B, Patel D, Gulati M. Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease. Respiratory Research 2024, 25: 372. PMID: 39407223, PMCID: PMC11481565, DOI: 10.1186/s12931-024-03000-z.Peer-Reviewed Original ResearchConceptsCognitive interviewsContent validityExposure questionnaireMultidisciplinary teamSemi-structured interview guideEvidence of content validityFibrosing ILDsInterstitial lung diseaseRelevant exposuresFibrotic interstitial lung diseaseClinically relevant exposuresTrained interviewersInterview guideAssessment QuestionnaireQuestionnaireInterviewsLung diseaseAdultsTeamClinicPatientsSource of misunderstandingOccupational inhalation exposureValidityDisease
2023
EVALUATION OF CONTENT VALIDITY OF A NEW EXPOSURE ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH FIBROSING INTERSTITIAL LUNG DISEASES
SWAMINATHAN A, MCFATRICH M, MKUMBA L, WRIGHT L, REDLICH C, SNYDER L, REEVE B, OLSON A, GULATI M. EVALUATION OF CONTENT VALIDITY OF A NEW EXPOSURE ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH FIBROSING INTERSTITIAL LUNG DISEASES. CHEST Journal 2023, 164: a5103-a5104. DOI: 10.1016/j.chest.2023.07.3304.Peer-Reviewed Original ResearchProteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome
Singh I, Leitner B, Wang Y, Zhang H, Joseph P, Lutchmansingh D, Gulati M, Possick J, Damsky W, Hwa J, Heerdt P, Chun H. Proteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome. Pulmonary Circulation 2023, 13: e12220. PMID: 37091121, PMCID: PMC10113513, DOI: 10.1002/pul2.12220.Peer-Reviewed Original ResearchInvasive cardiopulmonary exercise testPASC patientsPost-acute sequelaeAcute sequelaeInfection syndromeUnexplained exertional intoleranceCardiopulmonary exercise testSystemic oxygen deliveryPersistent inflammatory stateVenous blood plasmaExertional intolerancePeak exerciseEndothelial dysfunctionHemodynamic profileInflammatory stateExercise testFibrotic processPathophysiological hallmarkAberrant protein expressionExpression of proteinsOxygen deliveryOxygen extractionProteomic profilingPatientsPhysiologic responsesAutoimmune comorbidities associated with sarcoidosis: a case-control study in the All of Us research program
Murphy M, Edemobi P, Leasure A, Gulati M, Miller E, Damsky W, Cohen J. Autoimmune comorbidities associated with sarcoidosis: a case-control study in the All of Us research program. Rheumatology Advances In Practice 2023, 7: rkad030. PMID: 38606002, PMCID: PMC11007907, DOI: 10.1093/rap/rkad030.Peer-Reviewed Original ResearchCase-control studyAutoimmune diseasesSarcoidosis patientsMultivariable analysisOdds ratioSarcoidosis casesUs Research ProgramDiverse cohortConcomitant autoimmune diseasesRace-matched controlsMultiple autoimmune diseasesAutoimmune comorbiditiesSarcoidosisPatientsLogistic regressionDiseaseSmall sample sizeCareful screeningCohortAssociationSample sizeComposite variablePrior studiesComorbiditiesStudy
2022
Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry
Swaminathan A, Hellkamp A, Neely M, Bender S, Paoletti L, White E, Palmer S, Whelan T, Dilling D, Baker A, Beegle S, Belperio J, Condos R, Cordova F, Culver D, Fitzgerald J, Flaherty K, Gibson K, Gulati M, Guntupalli K, Gupta N, Case A, Hotchkin D, Huie T, Kaner R, Kim H, Lancaster L, Lasky J, Lee D, Liesching T, Lipchik R, Lobo J, Luckhardt T, Mageto Y, Menon P, Morrison L, Namen A, Oldham J, Paul T, Zhang D, Porteous M, Raj R, Ramaswamy M, Russell T, Sachs P, Safdar Z, Shafazand S, Siddiqi A, Sigal B, Strek M, Suliman S, Tabak J, Walia R. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Annals Of The American Thoracic Society 2022, 19: 981-990. PMID: 35073248, PMCID: PMC9169123, DOI: 10.1513/annalsats.202105-589oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisMedian ZIP code incomeZip code incomeLung transplant programsLung transplantProspective outcomes registryClinical characteristicsOutcomes RegistryPulmonary fibrosisTransplant programsSocial determinantsLung transplant centersDisease severity measuresIPF-PRO RegistryLikelihood of deathYears of ageLung transplantationPrespecified covariatesU.S. registriesDifferential associationsTransplant centersTransplant eligibilityClinical trialsTherapeutic modalitiesPatientsCorrection to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
Todd JL, Neely ML, Overton R, Mulder H, Roman J, Lasky JA, de Andrade JA, Gulati M, Huang H, Leonard TB, Hesslinger C, Noth I, Belperio JA, Flaherty KR, Palmer SM. Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort. Lung 2022, 200: 19-19. PMID: 35166906, PMCID: PMC8881254, DOI: 10.1007/s00408-022-00516-3.Peer-Reviewed Original ResearchAssociation of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
Todd JL, Neely ML, Overton R, Mulder H, Roman J, Lasky JA, de Andrade JA, Gulati M, Huang H, Leonard TB, Hesslinger C, Noth I, Belperio JA, Flaherty KR, Palmer SM. Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort. Lung 2022, 200: 11-18. PMID: 35066606, PMCID: PMC8881240, DOI: 10.1007/s00408-021-00505-y.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisLung transplantRespiratory deathsPulmonary fibrosisClinical measuresOptimism-corrected C-indexRisk of mortalityVariable clinical courseIPF-PRO RegistryRegistry cohortComposite outcomeClinical courseMultivariable analysisUnivariable analysisPatient outcomesC-indexCirculating proteinFatal diseaseTransplantPatientsDeathFibrosisOutcomesAssociationRegistry
2021
Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib
Rahaghi F, Belperio JA, Fitzgerald J, Gulati M, Hallowell R, Highland KB, Huie TJ, Kim HJ, Kolb M, Lasky JA, Southern BD, Swigris JJ, de Andrade JA. Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib. Clinical Medicine Insights Circulatory Respiratory And Pulmonary Medicine 2021, 15: 11795484211006050. PMID: 33854398, PMCID: PMC8013629, DOI: 10.1177/11795484211006050.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisConsensus recommendationsAdverse eventsPulmonary fibrosisPrescribing informationManagement of comorbiditiesManagement of patientsAdverse event managementClinical trial dataEvidence-based literatureReal-world evidenceCytochrome P450 3A4Delphi consensus recommendationsConcomitant medicationsLiver dysfunctionTolerability issuesConcomitant administrationGastrointestinal effectsDisease progressionNintedanibComorbiditiesAppropriate managementTrial dataPatientsP450 3A4
2020
The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods.
Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, Lancaster L, Lindell K, Nathan SD, Raghu G, Gibson K, Gulati M, Mason W, Noth I, Schmidt B, Spino C, Staszak S, Stauffer J, Wolters PJ, Cosgrove GP, Flaherty KR. The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Annals Of The American Thoracic Society 2020, 17: 1620-1628. PMID: 32776789, DOI: 10.1513/annalsats.202001-035sd.Peer-Reviewed Original ResearchConceptsInterstitial lung diseasePatient RegistryClinician accessLarge multicenter registryMean diffusing capacityPositive smoking historyPercent of patientsIdiopathic pulmonary fibrosisTime of enrollmentIndividuals 18 yearsMulticenter registrySmoking historyPulmonary fibrosisSupplemental oxygenVital capacityLung diseaseMean agePatient populationAntifibrotic therapyApplicable biomarkersClinical informationDiffusing capacityPatientsClinical sitesRegistryEssential Components of an Interstitial Lung Disease Clinic Results From a Delphi Survey and Patient Focus Group Analysis
Graney B, He C, Marll M, Matson S, Bianchi P, Cosgrove G, Lee J, Collaborators P, Abrencillo R, Bascom R, Scholand M, Bhatt N, Case A, Chaudhary S, Culver D, Danoff S, Desai A, Dilling D, Glazer C, Gulati M, Gupta N, Hamblin M, Hamzeh N, Huie T, Kim H, King C, Kreider M, Lacamera P, Lancaster L, Luckhardt T, Mageto Y, Kottman R, McCormick J, Mehrad B, Menon P, Montesi S, Mooney J, Moore D, Moua T, Nambiar A, Oldham J, Patel D, Paul T, Perez R, Podolanczuk A, Ramaswamy M, Roe D, Saad M, Sandbo N, Schaumberg T, Schmidt S, Shea B, Shifren A, Strek M, Thavarajah K, Todd N, Veeraraghavan S, Weight S, Wolters P, Zibrak J. Essential Components of an Interstitial Lung Disease Clinic Results From a Delphi Survey and Patient Focus Group Analysis. CHEST Journal 2020, 159: 1517-1530. PMID: 33031832, PMCID: PMC7534733, DOI: 10.1016/j.chest.2020.09.256.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseILD clinicCaregiver focus groupsPhysician expertsInterstitial lung disease clinicPatient-centered medical careManagement of patientsPulmonary Fibrosis FoundationDelphi surveyILD expertsILD patientsDisease clinicMultidisciplinary careLung diseasePatient outcomesFocus groupsClinicPatientsMedical careStudy designRound 1Essential componentThree-roundCareFocus group analysisAssociation of neoepitopes with disease severity and respiratory hospitalization in patients with IPF
Oldham J, Todd J, Neely M, Mulder H, Overton R, Kim H, Gulati M, Leonard T, Palmer S, Noth I, Hesslinger C. Association of neoepitopes with disease severity and respiratory hospitalization in patients with IPF. 2020, 5188. DOI: 10.1183/13993003.congress-2020.5188.Peer-Reviewed Original ResearchAssociations between Patient-reported Outcomes and Death or Lung transplant in IPF: Data from the IPF-PRO Registry
Case AH, Hellkamp AS, Neely ML, Bender S, Dilling DF, Gulati M, Hotchkin DL, Huie TJ, Lancaster L, Snyder LD, Conoscenti CS, Palmer S. Associations between Patient-reported Outcomes and Death or Lung transplant in IPF: Data from the IPF-PRO Registry. Annals Of The American Thoracic Society 2020, 0: 699-705. PMID: 32040340, PMCID: PMC7258421, DOI: 10.1513/annalsats.201906-437oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPatient-reported outcomesLung transplantClinical variablesSt. George's Respiratory Questionnaire total scoreSGRQ activity scoreUnderwent lung transplantClinical risk factorsPredictors of mortalityHealth-related qualityQuestionnaire total scoreIPF-PRO RegistryProspective outcomes registrySGRQ symptomsComposite outcomeExercise capacityActivity scoreOutcomes RegistryPulmonary fibrosisRisk factorsPhysical activityPatientsUnivariable modelsTransplantWorse scores
2019
Patient Registries in Idiopathic Pulmonary Fibrosis
Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, Gulati M, Huie TJ, Lancaster LH, Roman J, Ryerson CJ, Kim HJ. Patient Registries in Idiopathic Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2019, 200: 160-167. PMID: 31034241, PMCID: PMC6635784, DOI: 10.1164/rccm.201902-0431ci.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisPatient RegistryPrecision medicine approachQuality of lifeThousands of patientsClinical characteristicsRegistry databasePatient populationLarge registriesDisease progressionClinical trialsPatient profilesRare diseasePatientsRegistryDisease severityMedicine approachFibrosisDiseaseAnalysis of biospecimensBroad spectrumCurrent practiceComorbiditiesLongitudinal dataPredictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry
Snyder L, Neely ML, Hellkamp AS, O’Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respiratory Research 2019, 20: 105. PMID: 31142314, PMCID: PMC6542049, DOI: 10.1186/s12931-019-1043-9.Peer-Reviewed Original ResearchConceptsRisk of deathLung transplantIPF-PRO RegistryPatient characteristicsDisease severityPulmonary fibrosisUS registryOxygen useBackgroundIdiopathic pulmonary fibrosisPredictors of deathIdiopathic pulmonary fibrosisVariable clinical courseAnalysis cohortLower FVCProgressive diseaseClinical courseLow DLCOMultivariable analysisMortality outcomesVital capacityMonth 30Diffusion capacityPatientsTransplantHigh mortality
2018
Predictors of death or transplant in patients with idiopathic pulmonary fibrosis in the IPF-PRO Registry
Snyder L, Neely M, Hellkamp A, O'Brien E, Flaherty K, De Andrade J, Conoscenti C, Leonard T, Bender S, Gulati M, Culver D, Kaner R, Palmer S, Kim H. Predictors of death or transplant in patients with idiopathic pulmonary fibrosis in the IPF-PRO Registry. 2018, pa2196. DOI: 10.1183/13993003.congress-2018.pa2196.Peer-Reviewed Original Research
2016
Netrin‐1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin‐Induced Pulmonary Fibrosis
Sun H, Zhu Y, Pan H, Chen X, Balestrini JL, Lam TT, Kanyo JE, Eichmann A, Gulati M, Fares WH, Bai H, Feghali-Bostwick CA, Gan Y, Peng X, Moore MW, White ES, Sava P, Gonzalez AL, Cheng Y, Niklason LE, Herzog EL. Netrin‐1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin‐Induced Pulmonary Fibrosis. Arthritis & Rheumatology 2016, 68: 1251-1261. PMID: 26749424, PMCID: PMC5547894, DOI: 10.1002/art.39575.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibiotics, AntineoplasticAntibodies, NeutralizingBiomechanical PhenomenaBleomycinCase-Control StudiesCell DifferentiationCollagenCollagen Type ICollagen Type I, alpha 1 ChainFibrosisFlow CytometryFluorescent Antibody TechniqueHeterozygoteHumansLeukocyte Common AntigensLeukocytes, MononuclearLungLung Diseases, InterstitialMiceMice, KnockoutMicroscopy, Electron, ScanningNerve Growth FactorsNetrin-1ProteomicsPulmonary FibrosisReverse Transcriptase Polymerase Chain ReactionScleroderma, SystemicTissue ScaffoldsTumor Suppressor ProteinsConceptsSSc-related interstitial lung diseaseInterstitial lung diseaseFibrocyte accumulationNetrin-1Lung extracellular matrixPulmonary fibrosisLung scaffoldsBleomycin-Induced Pulmonary FibrosisPeripheral blood mononuclear cellsBlood mononuclear cellsHealthy control subjectsNovel therapeutic targetSystemic sclerosisExtracellular matrixLung fibrosisLung diseaseMononuclear cellsControl subjectsLung microenvironmentHealthy controlsScleroderma patientsAberrant anatomyLung matrixPatientsTherapeutic target
2015
Chitinase 3–like–1 and its receptors in Hermansky-Pudlak syndrome–associated lung disease
Zhou Y, He CH, Herzog EL, Peng X, Lee CM, Nguyen TH, Gulati M, Gochuico BR, Gahl WA, Slade ML, Lee CG, Elias JA. Chitinase 3–like–1 and its receptors in Hermansky-Pudlak syndrome–associated lung disease. Journal Of Clinical Investigation 2015, 125: 3178-3192. PMID: 26121745, PMCID: PMC4563747, DOI: 10.1172/jci79792.Peer-Reviewed Original ResearchMeSH KeywordsAdipokinesAdultAnimalsApoptosisBiomarkersChitinase-3-Like Protein 1Disease Models, AnimalFemaleGlycoproteinsHermanski-Pudlak SyndromeHumansInterleukin-13 Receptor alpha2 SubunitLectinsMaleMiceMice, KnockoutPulmonary FibrosisReceptors, ImmunologicReceptors, ProstaglandinRespiratory MucosaConceptsHermansky-Pudlak syndromePulmonary fibrosisChitinase 3Pulmonary fibrosis progressionFibroproliferative repairCHI3L1 levelsFibrosis progressionLung diseaseHPS-4HPS patientsIL-13Rα2Effector functionsReceptor CRTH2Epithelial apoptosisFibrosisProtective roleDisease severityPotential biomarkersCHI3L1Major causeHPS-1Abnormal localizationPatientsCell deathSeverity
2006
Clinical profile, diagnosis and management of patients presenting with symptomatic pulmonary embolism.
Agarwal R, Gulati M, Mittal B, Jindal S. Clinical profile, diagnosis and management of patients presenting with symptomatic pulmonary embolism. The Indian Journal Of Chest Diseases & Allied Sciences 2006, 48: 111-4. PMID: 16696525.Peer-Reviewed Original ResearchConceptsSymptomatic pulmonary embolismPulmonary embolismClinical profileLow molecular weight heparinOutcomes of patientsPulmonary artery hypertensionManagement of patientsMolecular weight heparinArtery hypertensionVentricular dyskinesiaAggressive managementClinical featuresPredominant complaintWeight heparinPerfusion scanMean ageEarly diagnosisProspective assessmentPatientsEmbolismSuccessful outcomeStudy periodDiagnostic methodsDiagnosisOutcomes